AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8140872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2842206 — intervention group
Group type: EXPERIMENTAL
Intervention: nedocromil sodium (4 mg twice daily)
Number of subjects: 30
Study 2842206 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 31712421 — intervention group
Group type: EXPERIMENTAL
Intervention: suvorexant (20 mg)
Number of subjects: 30
Study 31712421 — intervention group
Group type: EXPERIMENTAL
Intervention: brotizolam (0.25 mg)
Number of subjects: 30
Study 31712421 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 31712421 — intervention group
Group type: EXPERIMENTAL
Intervention: suvorexant
Number of subjects: 30
Study 31712421 — intervention group
Group type: EXPERIMENTAL
Intervention: brotizolam
Number of subjects: 30
Study 28407408 — intervention group
Group type: EXPERIMENTAL
Intervention: High-stress parenting group (n=785) with adult children having disabilities
Number of subjects: 5628
Study 28407408 — intervention group
Group type: COMPARATOR
Intervention: Low-stress parenting group (n=4843) with adult children being healthy
Number of subjects: 5628
Study 25980923 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of platelet-rich plasma (PRP)
Number of subjects: 57
Study 23337558 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniosacral therapy (6 treatments over 4 weeks)
Number of subjects: 20
Study 23337558 — intervention group
Group type: COMPARATOR
Intervention: Control group (answered HIT-6 questionnaire twice before receiving treatment)
Number of subjects: 20
Study 21622496 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (measured in UK units, 8 g of ethanol) in quitters
Number of subjects: 698
Study 21622496 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (measured in UK units, 8 g of ethanol) in smokers
Number of subjects: 698
Study 18971524 — intervention group
Group type: EXPERIMENTAL
Intervention: Top decile group (orthostatic BP increase >7.8 mmHg)
Number of subjects: 605
Study 17116022 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-333369 alone (5 days 250 mg q12h; 5 days 500 mg q12h)
Number of subjects: 24
Study 17116022 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ) alone (3 days 100 mg q12h; 3 days 200 mg q12h; 22 days 300 mg q12h)
Number of subjects: 24
Study 17116022 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBZ (300 mg q12h) and RWJ-333369 (5 days 250 mg q12h; 5 days 500 mg q12h)
Number of subjects: 24
Study 12894480 — intervention group
Group type: EXPERIMENTAL
Intervention: Nikavir
Number of subjects: 60
Study 12894480 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 11099873 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen replacement therapy (ERT)
Number of subjects: 71
Study 11099873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 9255651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent furosemide administration
Number of subjects: 46
Study 9255651 — intervention group
Group type: COMPARATOR
Intervention: Continuous furosemide infusion
Number of subjects: 46
Study 3919832 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop drinking coffee altogether
Number of subjects: 33
Study 3919832 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop drinking coffee for five weeks, then drink boiled coffee
Number of subjects: 33
Study 3919832 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop drinking coffee for five weeks, then drink filter coffee
Number of subjects: 33
Study 3919832 — intervention group
Group type: COMPARATOR
Intervention: Continue with usual coffee intake
Number of subjects: 33
Study 25755259 — intervention group
Group type: EXPERIMENTAL
Intervention: Family CBT (FCBT)
Number of subjects: 123
Study 25755259 — intervention group
Group type: COMPARATOR
Intervention: Child CBT (CCBT)
Number of subjects: 123
Study 28848766 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent Physical Exercise Training (IPET) for 1 hour weekly for 1 year
Number of subjects: 387
Study 28848766 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent Physical Exercise Training (IPET) for 1 hour weekly for 1 year with adherence ≥70%
Number of subjects: 387
Study 28848766 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 387
Study 26481739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal 25-μg misoprostol
Number of subjects: 222
Study 26481739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 23880883 — intervention group
Group type: EXPERIMENTAL
Intervention: Tio plus SFC (18 μg once daily + 50/250 μg twice daily)
Number of subjects: 60
Study 23880883 — intervention group
Group type: COMPARATOR
Intervention: Tio (18 μg once daily)
Number of subjects: 60
Study 23880883 — intervention group
Group type: COMPARATOR
Intervention: SM (50 μg twice daily)
Number of subjects: 60
Study 23880883 — intervention group
Group type: COMPARATOR
Intervention: SFC (50/250 μg twice daily)
Number of subjects: 60
Study 21681869 — intervention group
Group type: EXPERIMENTAL
Intervention: Association Splitting (AS)
Number of subjects: 46
Study 21681869 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WL)
Number of subjects: 46
Study 17522609 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (50 mg/day)
Number of subjects: 821
Study 17522609 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined iron and zinc supplementation (50 mg/day iron and 14 mg/day zinc)
Number of subjects: 821
Study 17522609 — intervention group
Group type: COMPARATOR
Intervention: Zinc supplementation (14 mg/day)
Number of subjects: 821
Study 17522609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821
Study 17522609 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-only supplementation
Number of subjects: 821
Study 16813912 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-tip test
Number of subjects: 43
Study 16813912 — intervention group
Group type: COMPARATOR
Intervention: Voiding cystourethrogram
Number of subjects: 43
Study 15070888 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 micro g)
Number of subjects: 80
Study 15070888 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (400 micro g)
Number of subjects: 80
Study 11254789 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (5 mg/kg/day)
Number of subjects: 10
Study 11254789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11254789 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 10
Study 9038032 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment group
Number of subjects: 37
Study 9038032 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment group
Number of subjects: 37
Study 8508009 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic powder (daily dose, 800 mg)
Number of subjects: 0
Study 8508009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3494917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiologic and Type A behavior counseling
Number of subjects: 1012
Study 3494917 — intervention group
Group type: COMPARATOR
Intervention: Cardiologic counseling only
Number of subjects: 1012
Study 3494917 — intervention group
Group type: COMPARATOR
Intervention: No group counseling
Number of subjects: 1012
Study 30021690 — intervention group
Group type: COMPARATOR
Intervention: Orlistat 60-mg capsule
Number of subjects: 83
Study 30021690 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 48-mg tablet
Number of subjects: 83
Study 30021690 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 144-mg tablet
Number of subjects: 83
Study 30021690 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 24-mg tablet
Number of subjects: 83
Study 27103095 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral removal using nephroscope (Group 2)
Number of subjects: 210
Study 27103095 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral removal using cystoscope (Group 1)
Number of subjects: 210
Study 27103095 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous cystolithotripsy (PCCL) (Group 3)
Number of subjects: 210
Study 27103095 — intervention group
Group type: COMPARATOR
Intervention: All three techniques
Number of subjects: 210
Study 27103095 — intervention group
Group type: COMPARATOR
Intervention: All three groups
Number of subjects: 210
Study 24728578 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-CEF (carboplatin and weekly paclitaxel followed by CEF)
Number of subjects: 181
Study 24728578 — intervention group
Group type: COMPARATOR
Intervention: P-CEF (weekly paclitaxel followed by CEF)
Number of subjects: 181
Study 24728578 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-CEF (in triple-negative breast cancer)
Number of subjects: 181
Study 24728578 — intervention group
Group type: COMPARATOR
Intervention: P-CEF (in triple-negative breast cancer)
Number of subjects: 181
Study 24728578 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-CEF
Number of subjects: 181
Study 24728578 — intervention group
Group type: COMPARATOR
Intervention: P-CEF
Number of subjects: 181
Study 22242619 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring in addition to treatment
Number of subjects: 90
Study 22242619 — intervention group
Group type: EXPERIMENTAL
Intervention: More mentoring with fewer treatment sessions
Number of subjects: 90
Study 20185595 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/d)
Number of subjects: 1255
Study 20185595 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 1255
Study 20185595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1255
Study 18362420 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled intermittent coronary sinus occlusion (PICSO)
Number of subjects: 34
Study 18362420 — intervention group
Group type: COMPARATOR
Intervention: Control group (without PICSO)
Number of subjects: 34
Study 15701489 — intervention group
Group type: EXPERIMENTAL
Intervention: Role-play group (1-hour lecture plus 1-hour role-playing)
Number of subjects: 16
Study 15701489 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM) group (1-hour EBM journal club)
Number of subjects: 16
Study 15701489 — intervention group
Group type: COMPARATOR
Intervention: Role-play group
Number of subjects: 16
Study 15701489 — intervention group
Group type: COMPARATOR
Intervention: EBM group
Number of subjects: 16
Study 11340102 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic oil (GO) 8.2 mg/d (allyl sulfides) for 11 weeks
Number of subjects: 51
Study 11340102 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic powder (GP) 7.8 mg allicin/d for 11 weeks
Number of subjects: 51
Study 11340102 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 11 weeks
Number of subjects: 51
Study 11340102 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic oil (GO)
Number of subjects: 51
Study 9473976 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand motion direction
Number of subjects: 0
Study 9473976 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion completion time
Number of subjects: 0
Study 7940135 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased inspiratory carbon dioxide concentrations (95% O2; 5% CO2; endtidal CO2 approx. 6.5%)
Number of subjects: 15
Study 7940135 — intervention group
Group type: COMPARATOR
Intervention: Breathing room air
Number of subjects: 15
Study 2481163 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 515
Study 2481163 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 515
Study 2481163 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Nifedipine and Metoprolol
Number of subjects: 515
Study 2481163 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (in patients already on a beta-blocker)
Number of subjects: 515
Study 28760693 — intervention group
Group type: EXPERIMENTAL
Intervention: Taping with tension
Number of subjects: 23
Study 28760693 — intervention group
Group type: COMPARATOR
Intervention: No tape
Number of subjects: 23
Study 27237598 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches (TNP)
Number of subjects: 82
Study 27237598 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 82
Study 23757426 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-sensitizing (IS) strategy
Number of subjects: 2159
Study 23757426 — intervention group
Group type: COMPARATOR
Intervention: Insulin-providing (IP) strategy
Number of subjects: 2159
Study 23757426 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-sensitizing (IS) strategy in men
Number of subjects: 2159
Study 21691934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure (CP) applied during intubation
Number of subjects: 50
Study 21691934 — intervention group
Group type: COMPARATOR
Intervention: No cricoid pressure (CP) applied during intubation
Number of subjects: 50
Study 19344441 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Management Checkup (RMC)
Number of subjects: 0
Study 19344441 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 17356308 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 28
Study 17356308 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 28
Study 15331896 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (n = 25)
Number of subjects: 50
Study 15331896 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (n = 25)
Number of subjects: 50
Study 15331896 — intervention group
Group type: COMPARATOR
Intervention: Switching drugs after no improvement
Number of subjects: 50
Study 11422094 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg acetylsalicyclic acid (ASA)
Number of subjects: 270
Study 11422094 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg metoprolol
Number of subjects: 270
Study 11422094 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 270
Study 9153098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime plus betamethasone (n = 59)
Number of subjects: 142
Study 9153098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (n = 61)
Number of subjects: 142
Study 9153098 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 142
Study 8125421 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 6.25 mg
Number of subjects: 300
Study 8125421 — intervention group
Group type: COMPARATOR
Intervention: Control group (intravenous streptokinase)
Number of subjects: 300
Study 8125421 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 3 mg
Number of subjects: 300
Study 8125421 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (doses not specified)
Number of subjects: 300
Study 3337794 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 100 micrograms kg‐1
Number of subjects: 57
Study 3337794 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 50 micrograms kg‐1
Number of subjects: 57
Study 3337794 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 3.0 micrograms kg‐1
Number of subjects: 57
Study 3337794 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 1.5 micrograms kg‐1
Number of subjects: 57
Study 3337794 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 57
Study 3337794 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine and Buprenorphine (both dosages)
Number of subjects: 57
Study 3337794 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine and Morphine
Number of subjects: 57
Study 29569806 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (4.5 mg/m2/day in EXIST-1, titrated to trough 5-15 ng/mL; 10 mg/day in EXIST-2)
Number of subjects: 212
Study 29569806 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 212
Study 26938860 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin treatment for acne vulgaris for 6 months
Number of subjects: 88
Study 26938860 — intervention group
Group type: COMPARATOR
Intervention: Control group (no isotretinoin treatment)
Number of subjects: 88
Study 23848184 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g intravenous albumin for the first 3 days within the first week of ICU stay (group A)
Number of subjects: 21
Study 23848184 — intervention group
Group type: COMPARATOR
Intervention: No albumin treatment (group B)
Number of subjects: 21
Study 23911171 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless meters
Number of subjects: 47
Study 23911171 — intervention group
Group type: COMPARATOR
Intervention: Nonwireless meters
Number of subjects: 47
Study 21942435 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hydrocortisone (0.45 mg/kg IV)
Number of subjects: 66
Study 21942435 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose hydrocortisone (0.15 mg/kg IV)
Number of subjects: 66
Study 21942435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 18450517 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarenflurbil 800 mg twice per day
Number of subjects: 210
Study 18450517 — intervention group
Group type: COMPARATOR
Intervention: Tarenflurbil 800 mg twice per day for 24 months
Number of subjects: 210
Study 22305824 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapeziectomy
Number of subjects: 174
Study 22305824 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapeziectomy with palmaris longus interposition
Number of subjects: 174
Study 22305824 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapeziectomy with ligament reconstruction and tendon interposition
Number of subjects: 174
Study 15829988 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (PDE-5 inhibitor)
Number of subjects: 0
Study 12873331 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam detoxification (CDTX)
Number of subjects: 66
Study 12873331 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam maintenance treatment (CMT)
Number of subjects: 66
Study 9814449 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (DEFLA)
Number of subjects: 24
Study 9814449 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (PRED)
Number of subjects: 24
Study 8595686 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% (40 mg)
Number of subjects: 90
Study 8595686 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 2.5% (50 mg)
Number of subjects: 90
Study 8595686 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (2 ml)
Number of subjects: 90
Study 2574045 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic antagonists
Number of subjects: 0
Study 2574045 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior high blood pressure
Number of subjects: 0
Study 2574045 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to therapy
Number of subjects: 0
Study 1207275 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine infusion of 0.5 g/kg over 30 minutes
Number of subjects: 0
Study 1207275 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine infusion
Number of subjects: 0
Study 29636011 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone IV-PCA
Number of subjects: 80
Study 29636011 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil IV-PCA
Number of subjects: 80
Study 29636011 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hydromorphone and sufentanil IV-PCA
Number of subjects: 80
Study 29231540 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (acupuncture at GV and Jiaji combined with rehabilitation training)
Number of subjects: 90
Study 29231540 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture group (simple acupuncture)
Number of subjects: 90
Study 29231540 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation group (simple rehabilitation training)
Number of subjects: 90
Study 26178815 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan TDS
Number of subjects: 239
Study 26178815 — intervention group
Group type: COMPARATOR
Intervention: Placebo TDS
Number of subjects: 239
Study 23132445 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 oral nutritional supplements (TheraTears Nutrition for Dry Eyes)
Number of subjects: 18
Study 21240001 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer protocol (CP)
Number of subjects: 18
Study 18380771 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming group (n = 25)
Number of subjects: 50
Study 18380771 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 50
Study 16937747 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal breathing method
Number of subjects: 30
Study 16937747 — intervention group
Group type: COMPARATOR
Intervention: Dosimeter method
Number of subjects: 30
Study 14620923 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg daily)
Number of subjects: 132
Study 14620923 — intervention group
Group type: COMPARATOR
Intervention: Other antihypertensive agents (control)
Number of subjects: 132
Study 10906645 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glycolic acid gel, pH 3.52, applied once daily for 7 days and then twice daily for 2 weeks
Number of subjects: 12
Study 10906645 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel, pH 5.75
Number of subjects: 12
Study 10906645 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glycolic acid gel, pH 3.52
Number of subjects: 12
Study 8630662 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrogenated soybean oil (PHSO diet)
Number of subjects: 31
Study 8630662 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter diet
Number of subjects: 31
Study 8630662 — intervention group
Group type: COMPARATOR
Intervention: Partially hydrogenated fish oil (PHFO diet)
Number of subjects: 31
Study 8630662 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 31
Study 1427582 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin once daily plus metronidazole
Number of subjects: 325
Study 1427582 — intervention group
Group type: COMPARATOR
Intervention: Amikacin twice daily plus metronidazole
Number of subjects: 325
Study 6565300 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug information only
Number of subjects: 48